Royal Bank of Canada’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $0 | Buy |
408
+172
| +73% | +$290 | ﹤0.01% | 7427 |
|
|
2025
Q4 | $0 | Sell |
236
-306,036
| -100% | -$530K | ﹤0.01% | 7406 |
|
|
2025
Q3 | $517K | Buy |
306,272
+46,324
| +18% | +$54.8K | ﹤0.01% | 4455 |
|
|
2025
Q2 | $236K | Sell |
259,948
-268,708
| -51% | -$159K | ﹤0.01% | 5037 |
|
|
2025
Q1 | $237K | Buy |
528,656
+497,168
| +1,579% | +$292K | ﹤0.01% | 4572 |
|
|
2024
Q4 | $16K | Buy |
31,488
+9,796
| +45% | +$7.19K | ﹤0.01% | 6201 |
|
|
2024
Q3 | $20K | Sell |
21,692
-625,771
| -97% | -$580K | ﹤0.01% | 6106 |
|
|
2024
Q2 | $646K | Buy |
647,463
+644,396
| +21,011% | +$712K | ﹤0.01% | 3803 |
|
|
2024
Q1 | $4K | Sell |
3,067
-170,850
| -98% | -$194K | ﹤0.01% | 6507 |
|
|
2023
Q4 | $189K | Buy |
173,917
+157,315
| +948% | +$172K | ﹤0.01% | 5152 |
|
|
2023
Q3 | $19K | Buy |
16,602
+2,368
| +17% | +$3.22K | ﹤0.01% | 6201 |
|
|
2023
Q2 | $20K | Buy |
14,234
+13,058
| +1,110% | +$18K | ﹤0.01% | 6212 |
|
|
2023
Q1 | $2K | Buy |
1,176
+843
| +253% | +$1.18K | ﹤0.01% | 6779 |
|
|
2022
Q4 | $0 | Sell |
333
-2,721
| -89% | -$3.43K | ﹤0.01% | 7488 |
|
|
2022
Q3 | $3K | Sell |
3,054
-2,150
| -41% | -$3.16K | ﹤0.01% | 6900 |
|
|
2022
Q2 | $8K | Sell |
5,204
-3,272
| -39% | -$4.32K | ﹤0.01% | 6470 |
|
|
2022
Q1 | $13K | Sell |
8,476
-20,487
| -71% | -$31.8K | ﹤0.01% | 6835 |
|
|
2021
Q4 | $71K | Buy |
28,963
+12,670
| +78% | +$29.7K | ﹤0.01% | 6169 |
|
|
2021
Q3 | $41K | Buy |
16,293
+7,205
| +79% | +$18.5K | ﹤0.01% | 6276 |
|
|
2021
Q2 | $26K | Buy |
9,088
+4,475
| +97% | +$11.6K | ﹤0.01% | 6423 |
|
|
2021
Q1 | $11K | Sell |
4,613
-3,229
| -41% | -$7.75K | ﹤0.01% | 6766 |
|
|
2020
Q4 | $13K | Sell |
7,842
-195
| -2% | -$273 | ﹤0.01% | 6265 |
|
|
2020
Q3 | $8K | Sell |
8,037
-3,301
| -29% | -$2.92K | ﹤0.01% | 6002 |
|
|
2020
Q2 | $10K | Buy |
11,338
+8,262
| +269% | +$7.27K | ﹤0.01% | 5830 |
|
|
2020
Q1 | $3K | Sell |
3,076
-6,667
| -68% | -$6.64K | ﹤0.01% | 6191 |
|
|
2019
Q4 | $9K | Buy |
9,743
+1,745
| +22% | +$1.45K | ﹤0.01% | 6189 |
|
|
2019
Q3 | $8K | Buy |
7,998
+3,000
| +60% | +$3.11K | ﹤0.01% | 5849 |
|
|
2019
Q2 | $6K | Buy |
4,998
+341
| +7% | +$393 | ﹤0.01% | 6233 |
|
|
2019
Q1 | $6K | Buy |
4,657
+57
| +1% | +$71 | ﹤0.01% | 6201 |
|
|
2018
Q4 | $4K | Sell |
4,600
-745
| -14% | -$1.14K | ﹤0.01% | 6230 |
|
|
2018
Q3 | $11K | Sell |
5,345
-2,314
| -30% | -$4.86K | ﹤0.01% | 5945 |
|
|
2018
Q2 | $14K | Buy |
7,659
+4,655
| +155% | +$9.37K | ﹤0.01% | 5706 |
|
|
2018
Q1 | $7K | Buy |
3,004
+2,749
| +1,078% | +$6.45K | ﹤0.01% | 5834 |
|
|
2017
Q4 | $0 | Sell |
255
-10,644
| -98% | -$23.2K | ﹤0.01% | 6724 |
|
|
2017
Q3 | $27K | Buy |
10,899
+6,975
| +178% | +$17.3K | ﹤0.01% | 5794 |
|
|
2017
Q2 | $11K | Sell |
3,924
-3,762
| -49% | -$10.5K | ﹤0.01% | 5768 |
|
|
2017
Q1 | $23K | Sell |
7,686
-1,772
| -19% | -$5.03K | ﹤0.01% | 5555 |
|
|
2016
Q4 | $30K | Buy |
9,458
+4,640
| +96% | +$14.2K | ﹤0.01% | 5541 |
|
|
2016
Q3 | $17K | Sell |
4,818
-11,547
| -71% | -$31.9K | ﹤0.01% | 5599 |
|
|
2016
Q2 | $37K | Buy |
16,365
+9,392
| +135% | +$23K | ﹤0.01% | 5238 |
|
|
2016
Q1 | $18K | Sell |
6,973
-1,332
| -16% | -$2.97K | ﹤0.01% | 5530 |
|
|
2015
Q4 | $28K | Buy |
8,305
+530
| +7% | +$1.58K | ﹤0.01% | 5576 |
|
|
2015
Q3 | $19K | Sell |
7,775
-741
| -9% | -$1.92K | ﹤0.01% | 5586 |
|
|
2015
Q2 | $25K | Buy |
8,516
+5,146
| +153% | +$19.9K | ﹤0.01% | 5589 |
|
|
2015
Q1 | $13K | Buy |
3,370
+290
| +9% | +$1K | ﹤0.01% | 5492 |
|
|
2014
Q4 | $9K | Hold |
3,080
| – | – | ﹤0.01% | 5645 |
|
|
2014
Q3 | $8K | Sell |
3,080
-929
| -23% | -$2.24K | ﹤0.01% | 5542 |
|
|
2014
Q2 | $10K | Hold |
4,009
| – | – | ﹤0.01% | 5400 |
|
|
2014
Q1 | $10K | Buy |
4,009
+850
| +27% | +$2.5K | ﹤0.01% | 5425 |
|
|
2013
Q4 | $10K | Sell |
3,159
-206
| -6% | -$622 | ﹤0.01% | 5451 |
|
|
2013
Q3 | $11K | Buy |
3,365
+206
| +7% | +$652 | ﹤0.01% | 5376 |
|
|
2013
Q2 | $10K | Buy |
+3,159
| New | +$10.1K | ﹤0.01% | 5280 |
|
Other funds holding LCTX
BC
VCM
DC
RA
AC
Royal Bank of Canada's LCTX Position: Q1 2026 in Review
Royal Bank of Canada increased its Lineage Cell Therapeutics (LCTX) stake by 73% in Q1 2026, buying an estimated $290 and bringing the position to 408 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7427.
Royal Bank of Canada first reported a position in LCTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $646K in Q2 2024. 130 funds tracked by Wall St. Rank hold LCTX as of Q1 2026.
- Royal Bank of Canada held 408 shares of Lineage Cell Therapeutics worth $0 as of Q1 2026.
- Royal Bank of Canada bought 172 Lineage Cell Therapeutics shares in Q1 2026, an estimated $290.
- Lineage Cell Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7427 holding.
- Royal Bank of Canada first reported a position in Lineage Cell Therapeutics in Q2 2013 and has held it in 52 quarters since.
- Royal Bank of Canada's Lineage Cell Therapeutics position peaked at $646K in Q2 2024.
- 130 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.